A research team from the Badalona Applied Research Group in Oncology (B·ARGO), the Urologic Tumors Unit of the Institut Català d’Oncologia (ICO), and the Germans Trias i Pujol Research Institute (IGTP) has developed a new therapeutic strategy for patients with a specific subtype of metastatic prostate cancer that is resistant to standard chemotherapy with Docetaxel.
Published in the journal Frontiers in Pharmacology, this study proposes a new treatment based on a combination of kinase inhibitors for patients who no longer respond to Docetaxel. The team discovered that resistance to this drug is associated with the hyperactivation of the PI3K/AKT and MEK/ERK pathways, and investigated the possibility of inhibiting these pathways as a new therapeutic strategy in patients who maintain the function of PTEN, a negative regulator protein of the PI3K/AKT signaling pathway.
The results of the study were promising, prompting the team to conduct a clinical trial to evaluate the safety and effectiveness of this combination in patients with Docetaxel-resistant prostate cancer. Vicenç Ruiz de Porras and Adrià Bernat-Peguera, researchers at ICO-IGTP and co-first authors of the study, state that the results of this study „open the door to a new therapeutic strategy for those patients with PTEN wild-type tumors who have transitioned to Docetaxel and in whom, unlike PTEN-null patients, the efficacy of AKT inhibitors in monotherapy has not been demonstrated.“
Germans Trias i Pujol Research Institute
Ruiz, V., et al. (2024). Dual Inhibition of MEK and PI3Kβ/δ – a possible therapeutic strategy in PTEN-Wildtype Docetaxel-resistant metastatic prostate cancer. Frontiers in Pharmacology. doi.org/10.3389/fphar.2024.1331648